Cargando…

Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients

Viral variants with decreased susceptibility to HCV protease inhibitors (PIs) occur naturally and preexist at low levels within HCV populations. In patients failing PI monotherapy, single and double mutants conferring intermediate to high-level resistance to PIs have been selected in vivo. The abund...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirst, Mariana E., Li, Eric C., Wang, Cindy X., Dong, Hui-Jia, Liu, Chen, Fried, Michael W., Nelson, David R., Wang, Gary P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726766/ https://www.ncbi.nlm.nih.gov/pubmed/23922778 http://dx.doi.org/10.1371/journal.pone.0069698

Ejemplares similares

The use of HCV positive donors among non-HCV infected liver transplant recipients
por: Zaffar, Duha, et al.
Publicado: (2022)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Dilemma of HCV Infection in Renal Transplant Recipients
por: Ashry Ahmed Gheith, Osama
Publicado: (2011)

miRNA expression profiles in liver grafts of HCV and HIV/HCV‐infected recipients, 6 months after liver transplantation
por: Bulfoni, Michela, et al.
Publicado: (2021)

Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α(18)
por: Stross, Claudia, et al.
Publicado: (2016)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life
por: Sabbatini, Massimo, et al.
Publicado: (2018)

Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver
por: Zhang, Jin, et al.
Publicado: (2019)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan
por: Tsai, Ming-Chao, et al.
Publicado: (2021)

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia
por: Aissa Larousse, Jameleddine, et al.
Publicado: (2015)

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain
por: Jimenez-Sousa, María Ángeles, et al.
Publicado: (2016)

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients
por: Ferri, Flaminia, et al.
Publicado: (2019)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
por: Nutt, Jamie, et al.
Publicado: (2017)

The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era
por: Cotter, Thomas G., et al.
Publicado: (2021)

Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients
por: Sawinski, Deirdre, et al.
Publicado: (2015)

Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome
por: Nowak, Knut Michael, et al.
Publicado: (2016)

Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
por: Gambato, Martina, et al.
Publicado: (2023)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation
por: Wieczorek-Godlewska, Renata, et al.
Publicado: (2017)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

Classification of HCV NS5B Polymerase Inhibitors Using Support Vector Machine
por: Wang, Maolin, et al.
Publicado: (2012)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation
por: Han, Di, et al.
Publicado: (2021)

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014)

Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2012)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
por: Saalau-Bethell, Susanne M., et al.
Publicado: (2012)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
por: Duerr, Michael, et al.
Publicado: (2019)

Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort
por: Shepherd, Samantha J., et al.
Publicado: (2015)

Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection
por: Sillanpää, Maarit, et al.
Publicado: (2009)

Correction: Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2013)

Management of HCV Infection and Liver Transplantation
por: Schiano, Thomas D., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_dv7q69r78larpua4blmpivad3l